Takeda Pharmaceutical (TAK) Cost of Revenue (2017 - 2026)

Takeda Pharmaceutical's Cost of Revenue history runs 10 years deep, the most recent figure standing at $2.6 billion for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 1.99% year-over-year to $2.6 billion in Q1 2026; TTM through Mar 2026 was $16.1 billion, a 3.27% increase from a year earlier, with the FY2026 full-year figure at $10.4 billion, up 0.64% from the prior year.
• Cost of Revenue declined to $2.6 billion in Q1 2026 per TAK's latest filing, from $2.6 billion in the prior quarter.
• Across five years, Cost of Revenue topped out at $8.1 billion in Q3 2025 and bottomed at $2.2 billion in Q3 2022.
• The 5-year median for Cost of Revenue is $2.5 billion (2025), against an average of $3.4 billion.
• Across the five-year window, Cost of Revenue slipped 11.72% in 2022 and soared 226.94% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $2.4 billion in 2022, then increased by 8.81% to $2.6 billion in 2023, then declined by 2.77% to $2.5 billion in 2024, then rose by 4.78% to $2.6 billion in 2025, then fell by 1.87% to $2.6 billion in 2026.
• Per Business Quant, the three latest TAK Cost of Revenue figures stand at $2.6 billion (Q1 2026), $2.6 billion (Q4 2025), and $8.1 billion (Q3 2025).